For prostate cancer surveillance, NCCN guidelines recommend prostate cancer screening starting at age 40 for BRCA2 PV carriers, and that BRCA1 PV carriers begin shared decision-making surrounding prostate-specific antigen screening at age 40 with consideration of surveillance at annual intervals [72]. The gene discussed is BRCA1; the disease is prostate carcinoma.